Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 20/20 | 0.69 |
| ▸ | HTR1D | P28221 | 15/20 | 0.69 |
| ▸ | HTR1B | P28222 | 14/20 | 0.69 |
| ▸ | HTR1A | P08908 | 11/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR1E | P28566 | 2/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751315 | 0.84 | HTR1F (0.65) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7011824 | 0.83 | HTR1F (0.63) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7007941 | 0.82 | HTR1F (1.00) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7012811 | 0.79 | HTR1F (0.74) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7011498 | 0.79 | HTR1F (0.74) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7005021 | 0.77 | HTR1F (0.68) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7009821 | 0.77 | HTR1F (0.75) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL1121919 | 0.76 | HTR1D (0.68) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL7009425 | 0.75 | HTR1F (0.65) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7015495 | 0.75 | HTR1F (0.72) | HTR1FHTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | claimed |
| EP-1497292-B1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-06-14 | — | — | EP | claimed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | claimed |
| EP-1497292-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2005-01-19 | — | — | EP | claimed |
| WO-2003082867-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2003-10-09 | — | — | WO | claimed |
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| EP-1497292-B1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-06-14 | — | — | EP | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
| EP-1497292-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003082867-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HTR1F 244/4885HTR1D 59/4885HTR1B 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.